Join
Live feed
·
PRReleasevia Quantisnow
ProKidney Corp. logo

ProKidney Announces Positive Interim Data from RMCL-002 Phase 2 Clinical Trial of Renal Autologous Cell Therapy (REACT®) for Diabetic CKD and Provides Corporate Updates

ByQuantisnow·Wall Street's wire, on your screen.
PROK· ProKidney Corp.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PROK (ProKidney Corp.) and more on Quantisnow.